BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Emerald Advisers LLC

Emerald Advisers LLC raised its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 4.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,150,868 shares of the company’s stock after purchasing an additional 47,360 shares during the period. BridgeBio Pharma comprises 1.2% of Emerald Advisers LLC’s holdings, making the stock its 25th largest position. Emerald Advisers LLC owned about 0.61% of BridgeBio Pharma worth $31,580,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC grew its holdings in BridgeBio Pharma by 85.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock valued at $28,000 after purchasing an additional 472 shares during the period. Advisors Asset Management Inc. boosted its stake in shares of BridgeBio Pharma by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock worth $117,000 after acquiring an additional 1,645 shares during the last quarter. Avanza Fonder AB acquired a new stake in shares of BridgeBio Pharma in the fourth quarter worth approximately $181,000. First Bank & Trust acquired a new stake in shares of BridgeBio Pharma in the fourth quarter worth approximately $205,000. Finally, Moss Adams Wealth Advisors LLC acquired a new stake in shares of BridgeBio Pharma in the fourth quarter worth approximately $208,000. 99.85% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CFO Brian C. Stephenson sold 4,148 shares of BridgeBio Pharma stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $36.16, for a total value of $149,991.68. Following the completion of the sale, the chief financial officer now directly owns 102,464 shares of the company’s stock, valued at approximately $3,705,098.24. The trade was a 3.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the business’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $32.96, for a total value of $197,760,000.00. Following the transaction, the insider now directly owns 19,260,971 shares of the company’s stock, valued at $634,841,604.16. The trade was a 23.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 9,579,739 shares of company stock valued at $323,171,901. 24.66% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

BBIO has been the topic of a number of research analyst reports. Citigroup lifted their price target on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Bank of America lifted their price objective on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Evercore ISI lifted their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, December 23rd. Scotiabank lifted their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Friday, February 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $49.00 price objective on shares of BridgeBio Pharma in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.20.

BridgeBio Pharma Stock Up 2.5 %

NASDAQ:BBIO opened at $34.77 on Friday. BridgeBio Pharma, Inc. has a 52 week low of $21.62 and a 52 week high of $39.47. The company has a market capitalization of $6.61 billion, a P/E ratio of -12.20 and a beta of 1.07. The stock’s fifty day moving average is $34.08 and its two-hundred day moving average is $29.09.

BridgeBio Pharma (NASDAQ:BBIO) last posted its earnings results on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to the consensus estimate of $4.04 million. Sell-side analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.